A number of glycosaminoglycan (GAG) species related to heparin, dermatan sulfate (DeS) and chondroitin sulfate were tested for their ability to interfere with the physiological expression and/or pathological overexpression of the TGF-β1 gene. The influence of the molecular weight, molecular weight distribution, degree of sulfation and location of the sulfate groups was examined in an attempt to unveil fine relationships between structure and activity. The nature of the polysaccharide plays a major part, heparins proving able to inhibit both basal and stimulated TGF-β1 gene expression, DeSs being essentially inactive and chondroitin sulfates only inhibiting stimulated TGF-β1 gene expression. Within this frame, the particular physical and chemical properties of some GAGs appear to further modulate TGF-β1 gene response. Judging from our investigation, chondroitin sulfates seem the most promising for potential pharmacological applications in disorders characterized by fibrogenic TGF-β1 overexpression.
Introduction
Transforming growth factor β1 (TGF-β1) is a key tissue repair cytokine. Its actions in promoting the production and deposition of extracellular matrix (ECM) are essential to normal tissue repair following injury. On the other hand, TGF-β1 overexpression is a common feature of several inflammatory and fibrotic disorders, and a sustained or excessive TGF-β1 expression is believed to have a clearly causal role in the pathogenesis of human and experimental fibrotic disease (Border and Ruoslahti 1992; Border and Noble 1994) .
In many experimental models, inhibiting TGF-β1 bioactivity prevents the accumulation of ECM and fibrosis. This has been thoroughly investigated in renal diseases. There is an evident interest in developing drugs and methods to inhibit TGF-β1 and hopefully thereby prevents fibrosis in humans. Strategies proposed so far to inhibit the TGF-β1 loop primarily rely on the effect on TGF-β1 protein of inhibitory antibodies (Border et al. 1990; Sharma et al. 1996) ; natural TGF-β1 inhibitors-i.e. the decorin core protein (Border 1992; Isaka et al. 1996) , the latency-associated peptide, the pro-region of TGF-β1 (Böttinger et al. 1996) ; and soluble TGF-β1 receptors (Isaka et al. 1999) or on the TGF-β1 mRNA ready to be translated by specific antisense oligonucleotides (Akagi et al. 1996; Kashihara et al. 1997) . Antibodies against the α(v)β6 integrin that prevents latent TGF-β activation have shown promise in experimental studies (Puthawala et al. 2008) . Small-molecule inhibitors of TGF-β1-receptor activity proved effective in animal models of fibrosis (Varga and Pasche 2009) . Imatinib mesylate and related tyrosine kinase inhibitors also block TGF-β1 pathways and prevent fibrotic responses (Pannu et al. 2008) . All these strategies were effective in preventing fibrosis in different models, both in the kidney and in other organs. Very limited experience in humans is available as yet. Anti-TGF-β1 monoclonal antibody was assessed in a small trial of early systemic sclerosis, with disappointing results (Varga and Pasche 2009) .
Although no side effects were reported in the animals treated, indicating that short-term TGF-β1 blockade is tolerable, by inducing a total, non-selective interruption of the action of TGF-β1, these strategies might lead to spontaneous immune activation (Kulkarni et al. 1993) , epithelial hyperplasia and malignant cell transformation (Markowitz et al. 1995) and impaired wound healing. All previous TGF-β1 inhibiting strategies were only tested in short-term studies, so the possibility of adverse long-term consequences of these approaches cannot be excluded. Alternative strategies have consequently been proposed and/or investigated that aim:
(i) to inhibit only the pathological overexpression of TGF-β1; or (ii) to inhibit only its pro-fibrotic activity, leaving its antiinflammatory, immunosuppressive and anti-mitogenic activity unaffected.
As regards the latter, attention has focused on putative downstream mediators of TGF-β-induced fibrosis with a view to pharmacologically separating this potentially beneficial bioactivity from the other effects of TGF-β1 (Clarkson et al. 1999; Ikawa et al. 2008) .
The feasibility of modulating only TGF-β1 overexpression at gene level was investigated at our laboratory. We had previously reported that chronic therapy with a number of glycosaminoglycan (GAG) formulations prevents and cures experimental diabetic nephropathy (Gambaro et al. 1992 (Gambaro et al. , 1994 . Although various mechanisms have been suggested to explain the reno-protective effect of GAGs, the observation that they prevented the diabetes-associated induction of glomerular and tubular TGF-β1 gene expression suggests that inhibiting TGF-β1 overexpression is one of the primary targets of the GAGs' action (Ceol et al. 2000) . The molecular mechanism behind our GAG formulations was investigated in more detail in mesangial cells cultured in both high glucose concentrations and phorbol-12-myristate-13-acetate (PMA; Ceol et al. 2000) : the GAGs suppressed the TGF-β1 mRNA levels, protein and bioactivity induced by high glucose levels or PMA without interfering with TGF-β1 receptor binding, or intra-or post-receptor signaling. In experiments using TGF-β1 promoter-reporter gene constructs, it was demonstrated that low-molecular-weight (LMW) heparins inhibit TGF-β1 promoter activity stimulated by high glucose levels or PMA with little effect on basal activity (Weigert et al. 2001) . On the whole, our results suggest that some GAG formulations could exert their inhibitory effect on any excessive TGF-β1 de novo formation without affecting basal TGF-β1 expression. This is consistent with findings that GAG treatment had little effect on renal TGF-β1 mRNA levels in nondiabetic animals (Ceol et al. 2000) .
That GAG treatment should prevent only the activated state (induced by PMA or high glucose levels) may be explained by the fact that TGF-β1 gene expression is regulated by at least two different transcription factors, one of which controls basal transcription, whereas the other transcription factor (AP1) responds to PMA (Kim et al. 1989) .
Our in vivo long-term studies (lasting 8 and 12 months) demonstrated that inhibiting TGF-β1 with GAGs is safe, since no autoimmune-like disease, excess mortality or cancers were observed (Gambaro et al. 1992 (Gambaro et al. , 1994 . We hypothesize that these results are due to the GAGs selectively inhibiting TGF-β1 overexpression, without affecting basal, physiological TGF-β1 expression.
On the other hand, preliminary data have shown that GAGs may differ hugely in how they affect TGF-β1 gene expression, depending on their molecular structure. Indeed, some are almost ineffectual, whereas others may inhibit basal gene expression too.
The aim of the present study was to screen GAG structure for the motifs responsible for their capacity to inhibit TGF-β1 overexpression. This is a key step in our understanding of the structure-activity relationships, and our ability to rationally design novel drugs capable of preventing and/or curing TGF-β1-related diseases, drugs that are: (i) devoid of anticoagulant properties, which might make the chronic use of some GAGs unsafe; and (ii) endowed with a favorable bioavailability, enabling their oral administration, for instance.
To clarify the role of molecular weight, degree of sulfation, sulfate position and specific functional sequences, we investigated the inhibitory effect of different natural GAGs and some of their semi-synthetic derivatives on TGF-β1 mRNA levels induced by PMA stimulation in primary cultures of renal mesangial cells. It appears that structural differences in the polysaccharide backbones and sulfation patterns represent major discriminating characteristics in the inhibition of TGF-β1 overexpression. Chondroitin sulfates (chondroitin sulfate-4S and chondroitin sulfate-6S, as well as 4,6-disulfated chondroitin) emerged as interesting potential pharmacological solutions for inhibiting only the pathological expression of TGF-β1.
Results

Chemical and biophysical properties of GAGs
Heparin, DeSs and chondroitin sulfates were chosen for this study, and their structures are shown in Figure 1 . The GAGs tested are characterized by average molecular weights ranging from 3400 to over 100,000, and degrees of sulfation (n s , number of sulfate groups per disaccharide unit) in the range 1-3.9. Some heparin and galactosaminoglycan derivatives with different sulfation patterns were also prepared and characterized. The physical and chemical characteristics of the compounds we tested are summarized in Tables I-III. NMR spectra indicated a good structural homogeneity and were used to assess the degree of sulfation in different positions (Guerrini et al. 2005) . The commercial chondroitin sulfates showed the well-known mixed-type sulfation pattern corresponding to 46% 6-O-sulfation for Ch-4S and 34% 4-O-sulfation for Ch-6S. Some 4-O-mono-sulfated residues were retained in the 4,6S-disulfated derivative, whereas for the O-sulfated derivatives of DeS both 4-and 6-OH of galactosamine residues were extensively sulfated. To ascertain the importance of the N-acetyl groups in eliciting the inhibitory activities, the corresponding "heparin-like" N-sulfated derivatives-where the original N-acetyl groups were substituted by N-sulfate groups-were also obtained from both chondroitin and DeS (Pescador et al. 1991) .
Among the heparin derivatives, some were prepared with higher or lower degrees of sulfation than normal heparin. The undersulfated derivatives had a similar charge density (n s ), but differed in their desulfated position (two of iduronic acid or six of glucosamine). The oversulfated species were almost completely sulfated low-molecular-weight derivatives, with incomplete sulfation at position 2 of iduronic acid and an unusually high content of sulfate at position 3 of glucosamine.
For the purposes of comparison, low-molecular-weight derivatives of heparin and 2-O-des Hep were prepared by means of a deamination reaction (Pisano et al. 2005) ; the chains of these derivatives terminated with a 2,5-anhydromannitol residue at the reducing end.
GAG effects on TGF-β1 overexpression
The levels of basal and PMA-stimulated TGF-β1 gene expression are shown in Figure 2 .
Under these conditions, all tested GAGs only marginally inhibited mesangial cell proliferation (data not shown). This was a necessary condition for the effect of different GAGs on TGF-β1 expression to be compared.
The GAGs were able to inhibit basal and PMA-stimulated TGF-β1 expression to different extents (Tables I-III) . Among the heparin derivatives (compounds 1-11; Table I ), the active GAGs (compounds 1-4, 7 and 10) inhibited both basal and PMA-stimulated cytokine expression. For compounds 1, 6 and 10, it was especially evident that said effects did not relate simply to the degree and/or pattern of sulfation, but seemed to decline with decreasing molecular weights, those in the range 6000-20,000 Da being compatible with a favorable response (compounds 1-4). For oversulfated heparin (Mw 8200, compound 7) and 3-O-sulfate-enriched LMW heparin (compound 10), the increased degree of sulfation seemed to compensate for the effect of the lower molecular weight, and O-desulfation of heparin limited the effect on both basal and PMA-stimulated activity (compound 3); in the case of 2-O-desulfation, there was evidence of a loss of inhibitory activity with decreasing molecular weights (compounds 4-6).
DeS and its derivatives were essentially inactive (Table II) . It was only in the case of a high-molecular-weight 4,6-disulfated DeS (compound 15) that any inhibition of TGF-β1 expression was observed (with a greater efficacy in inhibiting basal than PMA-stimulated TGF-β1 expression). Activity is expressed as IC 50 (nM), mean ± SD of the basal or PMA-stimulated TGF-β1 gene expression by the corresponding GAG; activity values are the results of at least three different experiments. NA means not assessed, either because the compound disclosed a very low activity and it was impossible to determine the IC 50 up to the concentration shown in brackets (>concentration) or because the compound was very active with an IC 50 lower than the lowest tested concentration shown in brackets (<concentration). Concentrations are expressed using the average molecular weight of the polymer (Mw); pD, polydispersity index (Mw/Mn ratio) n s , degree of sulfation evaluated as the number of sulfate groups per disaccharide unit. 
GAGs and TGF-β1 inhibition
On the other hand, with the exception of compound 20 (LMW Ch-6S), which was inactive, the chondroitin sulfates (compounds 18-23) were active and remarkably selective, invariably inhibiting PMA-stimulated TGF-β1 expression, but not its basal expression (Table III) . The chondroitin sulfates' molecular weight (11,400-107,700 Da) affected the response to only a limited extent, higher molecular weights generally proving more selective. The chondroitin sulfates with a degree of sulfation between 1 and 2.6 showed a comparable activity, whereas lower degrees of sulfation coincided with a higher selectivity. Adding sulfate groups at position 6 of galactosamine had different effects on DeS and chondroitin 4-sulfate. Although 90% of 6-O-sulfated chondroitin sulfate retained the same activity as the 46% 6-O-sulfated natural starting material, further 6-O-sulfation induced a stronger inhibition of the basal than of the stimulated activity of DeS. N-sulfation of both chondroitin and DeSs led to virtually no inhibition of either basal or PMA-stimulated TGF-β1 expression.
Discussion and conclusions
In this paper, we examine the inhibitory effects on the TGF-β1 gene of a number of GAG derivatives related to Activity is expressed as IC 50 (nM), mean ± SD of the basal or PMA-stimulated TGF-β1 gene expression by the corresponding GAG; activity values are the results of at least three different experiments. NA means not assessed, either because the compound disclosed a very low activity and it was impossible to determine the IC 50 up to the concentration shown in brackets (>concentration) or because the compound was very active with an IC 50 lower than the lowest tested concentration shown in brackets (<concentration). Concentrations are expressed using the average molecular weight of the polymer (Mw); pD, polydispersity index (Mw/Mn ratio); n s , degree of sulfation evaluated as the number of sulfate groups per disaccharide unit; -, not pertinent, because no residues were found in the structure. Activity is expressed as IC 50 (nM), mean ± SD of the basal or PMA-stimulated TGF-β1 gene expression by the corresponding GAG; activity values are the results of at least three different experiments. NA means not assessed, either because the compound disclosed a very low activity and it was impossible to determine the IC 50 up to the concentration shown in brackets (>concentration) or because the compound was very active with an IC 50 lower than the lowest tested concentration shown in brackets (<concentration). Concentrations are expressed using the average molecular weight of the polymer (Mw); pD, polydispersity index (Mw/Mn ratio); n s , degree of sulfation evaluated as the number of sulfate groups per disaccharide unit; -, not pertinent, because no residues were found in the structure. heparin, DeS and chondroitin sulfate. We had previously ruled out the possibility of the GAGs tested inhibiting mesangial cell proliferation, a necessary condition to enable us to compare the effect of different GAGs on TGF-β1 expression. In general, higher molecular weights and degrees of O-sulfation tended to achieve more effective responses, pointing to GAG-mediated ( perhaps receptorial) effects on the cell membrane capable of inducing an intracellular signaling pathway that can modulate the TGF-β1 gene. The existence of a GAG (heparin) receptor at the cell membrane level has already been hypothesized (Cavari et al. 1994) , and there are findings to suggest that it triggers an intracellular signaling cascade downstream (Savage et al. 2001) . Two alternative hypotheses might be proposed for the action of GAGs on the TGF-β1 gene, i.e. a direct effect of GAGs at a nuclear level on TGF-β1 gene transcription, or the GAGs' direct interference with the TGF-β1 peptide. Concerning the former hypothesis, it has been demonstrated that heparan sulfate can reach the cell nucleus in hepatocytes (Ishihara et al. 1986) . Although this could be the case for relatively small and normally sulfated heparins, the larger and more sulfated GAG molecules would be severely hindered in their biophysical permeation of the cell membrane. Their cellular uptake would therefore imply a hypothetical endocytotic process, but only exceedingly high heparin concentrations have been shown to displace AP1-binding proteins from the TGF-β1 gene promoter in experiments using electrophoretic mobility shift assay in mesangial cells (E.D. Schleicher, unpublished data). Since such concentrations are well above the range of concentrations shown to be effective in our experiments, this first hypothesis seems to be highly unlikely.
As for the second hypothesis, since TGF-β1 is the only growth factor capable of producing a positive feedback on its own synthesis (Sharma et al. 1996) , one may speculate that the effects produced by exogenous GAGs on the growth factor gene's expression rely on the GAGs interfering with the binding of TGF-β1 to betaglycan, a cell surface chondroitin sulfate/heparan sulfate proteoglycan co-receptor for TGF-β1 in some cell types. A decrease in the TGF-β1 sequestration by GAG chains of β-glycan would thus lead to a decreased TGF-β1 synthesis. It has been shown, however, that TGF-β1 and betaglycan interact at a core protein level rather than at a GAG chain level (Eickelberg et al. 2002) . In previous experiments, moreover, we ruled out any direct effect of GAGs on TGF-β1 protein and bioactivity by adding 10 µg/mL GAGs (i.e. a more than 1000-fold molar excess) to active recombinant TGF-β1 (1 ng/mL) in a mink lung cell assay, a proliferation test for evaluating the antimitogenic effect, or bioactivity, of TGF-β1 (Ceol et al. 2000) . Adding GAGs had no effect on the proliferation of mink lung cells in control or TGF-β1-treated cultures, and no TGF-β1-blocking effect was observed (Ceol et al. 2000) . Finally, to avoid other unpredictable and unwanted interactions between GAGs and growth factors (including TGF-β1), we used 2% Ultroser, which is devoid of TGF-β1, in our experiments instead of 15% fetal calf serum.
Taken together, these considerations lend support to the idea that the action of exogenous GAGs on TGF-β1 gene expression is not mediated by any direct interference of GAGs with the TGF-β1 peptide, nor to any other secondary interactions of GAGs that might affect cell biology.
Previously published data indicate that physiological TGF-β1 expression depends on the activation of AP1 sites, whereas the cytokine's pathological expression induced by PMA or high glucose levels is modulated by Sp1 sites in the promoter (Weigert et al. 2001) . Our data are consistent with the existence of different GAG receptor sites or with the differential inhibition of a common receptor as a result of disease-induced conformational changes.
Different GAGs exhibit substantially different biological responses. In particular, their ability to affect TGF-β1 expression relates to their structure. Heparins significantly affect both basal and PMA-stimulated cytokine production (and the latter in particular), the outcome differing as a function of the GAGs' molecular weights. Chondroitin sulfates, and especially those with molecular weights higher than 20,000 Da, inhibit PMA-stimulated, but not basal expression, whereas DeS proves basically ineffectual (and where it does have an effect, as observed for its 4,6-disulfated derivative, its action affects both basal and stimulated TGF-β1 expression). Earlier results reported by our group on DeS in a similar model (Ceol et al. 2000) are at odds with the present findings, however, since a dose-dependent inhibition of the PMA-stimulated, but not of the basal TGF-β1 mRNA levels, was recorded. The DeS considered in the previous study was not tested in the present case because it is no longer available. More studies are consequently needed to investigate the structure-function relationship in DeS derivatives.
The different action on basal and PMA-stimulated TGF-β1 expression appears to depend not on specific molecular weights or overall sulfation (n s ), as shown by the data in Tables I-III , but on the charge distribution within the GAG's structure. Although the analysis of possible structure-activity relationships fails to consider the common microheterogeneity of GAG chains, charge location has an impact on biological response. In fact, preliminary conformational considerations suggest that selectivity in TGF-β1 inhibition is driven by the appropriate mutual arrangement of the negatively charged groups in the GAG structure. Conceivably, chondroitin sulfates would essentially only recognize "pathological" receptor sites, whereas some heparins are able to adapt to physiological and pathological targets, whereas all but one of the DeSs tested were unable to bind them efficiently.
Considering the composition of the GAGs we tested, the most interesting disaccharide sequence is a glucuronic acid (GlcA) β1-3 linked to an N-acetylated galactosamine. A major structural difference between DeS and Ch-4S consists in their uronic acid residues, respectively, IdoA and GlcA. Although the local flexibility induced by the existence of more than one equienergetic configuration of IdoA and IdoA-2S residues in DeS is known to facilitate protein binding (Casu et al. 1988; Raman et al. 2003) , local flexibility usually modulates interactions on a level with one or more relatively short clusters of basic protein residues (Mulloy and Linhardt 2001; Casu et al. 2010) . In the present case, relatively stiff chains such as those predicted for ChS-the uronic acid residues of which consist of the conformationally stable GlcA hydrogen bonded to GAGs and TGF-β1 inhibition neighboring GlcNAc residues (Almond and Sheehaman 2000) -probably favor interactions over extended stretches of the GAG, and rigidity seems to enable the precise recognition of a biological target and a lesser adaptability to different (yet similar) receptor site(s). Hence, the high selectivity exhibited by chondroitin sulfate for the mechanism of PMA-stimulated TGF-β1 expression.
Finally, heparins seem to impair both cytokine expression pathways. This can be reasonably explained by their different overall structure, including the type of glycosidic linkage and the presence of glucosamine instead of galactosamine, as well as its marked structural heterogeneity due to the presence of both L-IdoA and GlcA.
The selective inhibition of the TGF-β1 fibrogenic pathway could have an enormous impact in preventing or curing a number of diseases, some of which are very common (i.e. the long-term complications of diabetes), others very rare (i.e. idiopathic lung fibrosis), for which no really effective agents are currently available. The solution could be a GAG or a rationally designed analogue; it would have no anticoagulant effect and no capability for inducing anti-platelet antibodies; it would preferably demonstrate a good oral bioavailability, and a T/2 long enough to allow for a single daily dosage. The present study addressed the recognition of the GAG molecular structures needed for such a specific TGF-β1 gene inhibition. Given the demonstration of well-defined structural differences relating to GAG response/selectivity, our results provide a positive input for the identification of pharmacologically useful GAG analogs obtainable from heparin, or, better still, from the nonanticoagulant, selective chondroitin sulfate structural type.
Materials and methods
All solvents and reagents were of analytical grade (Aldrich Milano, Italy) and were used as received.
GAGs and derivatives
Pig mucosal heparin (Hep, compound 1 in Tables I-III) , pig mucosal dermatan sulfate (DeS, compounds 12 and 13) and LMW-DeS (compound 14) were a gift from the Laboratori Derivati Organici in Trino Vercellese, Italy. Chondroitin sulfate type-A from whale cartilage (Ch-4S, compound 18) and chondroitin sulfate type-C from shark cartilage (Ch-6S, compound 19) were purchased from Sigma (Milan, Italy). The other compounds were prepared using the methods in the literature. 2-O-desulfated heparin (2-O-des Hep; compound 4) was prepared using an alkaline heparin treatment (Jaseja et al. 1989 ); 6-O-des Hep (compound 3) was prepared by partial desulfation under solvolytic conditions (Nagasawa and Inoue 1976) , followed by resulfation of the free amino groups with the sulfur trioxide-trimethylamine complex in a basic aqueous medium (Lloyd et al. 1971) . Supersulfated heparins of low, very low and ultra-low molecular weight compound 7; compound 8; compound 9) were prepared by making the heparin react with chlorosulfonic/sulfuric acid (Naggi et al. 1987 ) and using different reaction times to obtain products with different mean molecular weights. 3-O-sulfated glucosamine-enriched LMW heparins (compounds 10 and 11) were prepared by partial desulfation of ssLMW-Hep under solvolysis by dimethyl sulfoxide/MeOH at 65°C using different reaction times (Naggi et al. 2001) , followed by resulfation of the free amino groups (Lloyd et al. 1971) . LMW heparin (compound 2) and LMW-2-O-des heparins (compounds 5 and 6) were prepared by controlled nitrous acid depolymerization, as described by Pisano et al. (2005) . LMW-DeS (compound 14) and LMW Ch-6S (compound 20) were obtained by size exclusion fractionation of the corresponding high-molecularweight GAGs.
Dermatan and chondroitin 4,6-O-sulfate derivatives (DeS-4,6S, compound 15; LMW DeS-4,6S, compound 16; Ch-4,6S, compound 21) were prepared by means of a treatment with excess sulfur trioxide pyridine complex in dimethylformamide, as described by Gigli et al. (1993) , using compounds 12, 14 and 18, respectively, as starting products. N-sulfated DeS (DeS-NS, compound 17) and chondroitin sulfate (Ch-N,4,6S-1, compound 22; Ch-N,4,6S-2, compound 23) were prepared by removing the original acetamido group by hydrazinolysis (Shaklee and Conrad 1986) and resulfating the resulting free amino groups with trimethylamine SO 3 (Naggi et al. 1989) .
Compounds 22 and 23 are two preparations of Ch-N,6-sulfate. All samples were desalted by dialysis against deionized water through 2000 Da cut-off tubes (Spectra/pore dialysis membrane, Spectrum Laboratories Inc., Breda, the Netherlands) or by fractionation on a 2.5 × 100 cm Sephadex G10 (GE Healthcare Europe, Milan, Italy) column, eluted with 10% EtOH in water using UV peak detection at 210 nm. All products gave a single high-performance liquid chromatography (HPLC) peak.
The sulfation pattern of the GAG derivatives was characterized by 1 H-and 13 C-NMR spectroscopy (Guerrini et al. 2005 ) using a Bruker AMX 500 spectrometer equipped with a 5 mm 1 H/X inverse probe, and/or a Bruker AMX 400 spectrometer equipped with a 10 mm 13 C probe, in D 2 O solution (15 mg/ 0.5 mL 99.99% D 2 O). In particular, 6-O-desulfation of heparin was confirmed in the 13 C-NMR spectrum by the reduced intensity of the characteristic 6-O-sulfate signal of N,6S-GlcN at 68.6 ppm and the appearance of a NS-GlcN signal at 62 ppm of 6-OH. Heparin 2-O-desulfation was confirmed by 13 C-NMR by the reduced intensity of the characteristic signal at 102 ppm of C-2 of iduronic acid 2-O-sulfate (IdoA-2S). The degree of 3-O-sulfation of glucosamine residues was evaluated from the area of signal at 5.5 ppm in 1 HNMR spectra (Santini et al. 1997) or from the area ratio of C-2 signals of N,3S-GlcN at 59.5/3.55 ppm and of NS-GlcN at 56/3.72 ppm in heteronuclear multiple-quantum correlation experiments. For the chondroitin sulfates, differentiation between the C6 and C4 sulfation of galactosamine was based on the assignments of 13 C-NMR signals in the literature (Hamer and Perlin 1976) . Molar ratios C4S/C6S were determined from the area ratio of C-2 signals of the galactosamine residue of the two components. Molecular weight analysis, determining the mean molecular weights (Mw) and polydispersion, was done by gel permeation chromatography-HPLC using the triple detector technology (Bertini et al. 2005 ) on a Viscotex instrument equipped with a VE112 pump, a 100 μL injector and a TDA302 detector with refractive index, viscosimeter, and 90°light scattering systems. The eluent was 0.1 M NaNO 3 (flow 0.6 mL/min). Samples were dissolved in the mobile phase solution (15 mg/mL). The degree of sulfation, expressed as the number of sulfate groups per disaccharide unit, was determined by NMR.
Cell cultures and experimental model Mesangial cells isolated from porcine (Sus scrofa) glomeruli were cultured and characterized as described elsewhere (Kolm-Litty et al. 1998) . Cells were grown and expanded in RPMI 1640 with 15% fetal calf serum, 1 mM sodium pyruvate, 3 mM glutamine, nonessential amino acids, 100 U/mL penicillin, 100 µg/mL streptomycin, 0.5 µg/mL minocyclin and 10 mM glucose.
For experimental purposes, the cultures were washed with RPMI, then incubated with RPMI 1640 with 2% Ultroser. After 24 h of incubation in these experimental conditions, TGF-β1 gene expression was evaluated under basal conditions and after stimulation with 0.5 µM PMA in ethanol; for both conditions, parallel experiments were also run with or without different GAGs (concentrations were usually in the range 25-100 nM, unless stated otherwise; concentration is expressed using the mean molecular weight of the GAG being tested). The experiments lasted 9 h. Preliminary dose and time-course analyses were performed to choose these experimental conditions, i.e. GAG doses and test times. TGF-β1 gene expression was quantified by real-time polymerase chain reaction (PCR). GAG activity was expressed as the IC 50 (50% inhibition) of the basal or PMA-stimulated TGF-β1 gene expression.
Proliferation assay
The number of proliferating cells was measured on 24-well plates using a colorimetric method. Briefly, supernatants were removed, cells were washed with ice-cold PBS and fixed overnight with methanol at 4°C, then the wells were stained for 30 min with 1% methyl blue in 0.01 M borate buffer, pH 8.5. After repeated washing with borate buffer, the fixed stain (which is proportional to the number of proliferating cells) was subsequently eluted with 0.1 N HCl/ ethanol 1:1 (vol/vol) and read spectrophotometrically at 650 nm. The results obtained with this colorimetric method were confirmed by manually counting the cells under the light microscope by Trypan blue exclusion using a Neubauer chamber slide.
TGF-1 mRNA quantification by real-time PCR Real-time PCR was performed using the iCycler Thermal cycler (Bio-Rad, Hercules, CA) and SYBR Green I analysis, as described elsewhere (Del Prete et al. 2003) . The PCR standard for TGF-β1 and glyceraldehyde-3-phosphate dehydrogenase (G3PHD) consisted of known numbers of molecules of purified PCR products. After checking for specificity by polyacrylamide gel electrophoresis analysis, the PCR products were purified using MinElute PCR Purification Kit (Qiagen, Bothell, WA) and quantified by spectrophotometry using a 260 nm wave length. The number of copies/mL of standard was calculated according to the following formula: copies=mL ¼ 6:023 Â 10 23 Â C Â OD 260 Mw where C = 5 × 10 −5 g/mL for DNA and Mw is the molecular weight of the PCR product gene (base pairs × 6.58 × 10 2 g). Standards were serially diluted in log steps from 10 8 down to 10 1 copies in 1 μL volumes. The sensitivity of the PCR method using different primers was determined from the threshold cycle (Ct) values obtained with known quantities of purified PCR products. All calibration curves for purified PCR products of porcine TGF-β1 and G3PDH showed linearity over the entire quantification range with correlation coefficients r = 0.98, indicating a precise log-linear relationship. The slopes of the two genes were 3.59 and 3.6, respectively, demonstrating comparable PCR amplification efficiencies. The intra-run variability, calculated from duplicate samples for all the targets, showed an average SD for the threshold cycle of Ct 0.12 cycles. The primers employed for amplification using SYBR Green I were:
for G3PDH forward 5′-TCCGTGTCCCTACTGCCAAC-3′, reverse 5′-GTAGCCCAGGATGCCCTTGA-3′; for TGF-1 forward 5′-ACCGCCGAGCCCTGGATA-3′, reverse 5′-GCATGGTAGCCCTTGGGTTCA -3′;
The size of the PCR products amplified with primers for SYBR Green I analysis were G3PDH 131 bp and TGF-β1 130 bp.
The optimal concentration of primers (300 nM) and MgCl 2 (3 mM) was determined from preliminary experiments. The thermal cycling profile for G3PDH, and TGF-β1 consisted of: step 1, 95°C for 5 min; step 2, 94°C for 45′′; step 3, 60°C for 30′′ (steps 2 and 3 repeated for 40 cycles); step 4: melting curve. As SYBR Green I also binds to primer dimers formed nonspecifically during all PCRs, it was necessary to obtain the most favorable temperature for the analysis of each specific product. Melting curve analysis and PAGE confirmed the specificity of the amplification products. The quantification data were analyzed with the iCycler software and expressed as the ratio between the Starting Quantity mean of the target and of the housekeeping gene.
Statistical analysis
The IC 50 values were calculated by nonlinear logistic regression analysis using SAS software (SAS Institute Inc., Cary, NC). The IC 50 data are shown as mean ± SD confidence intervals. Data from at least three different experiments performed in duplicate were used for the analysis.
